69 related articles for article (PubMed ID: 9476930)
41. In vivo imaging of glucose uptake and metabolism in tumors.
Walker-Samuel S; Ramasawmy R; Torrealdea F; Rega M; Rajkumar V; Johnson SP; Richardson S; Gonçalves M; Parkes HG; Arstad E; Thomas DL; Pedley RB; Lythgoe MF; Golay X
Nat Med; 2013 Aug; 19(8):1067-72. PubMed ID: 23832090
[TBL] [Abstract][Full Text] [Related]
42. Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib.
Kasper B; Dimitrakopoulou-Strauss A; Pilz LR; Strauss LG; Sachpekidis C; Hohenberger P
Biomed Res Int; 2013; 2013():389672. PubMed ID: 23762842
[TBL] [Abstract][Full Text] [Related]
43. A review of controversies in the management of soft tissue sarcomas.
Deo SV; Manjunath NM; Shukla NK
Indian J Surg; 2012 Jun; 74(3):228-33. PubMed ID: 23730049
[TBL] [Abstract][Full Text] [Related]
44. The power of FDG-PET to detect treatment effects is increased by glucose correction using a Michaelis constant.
Williams SP; Flores-Mercado JE; Baudy AR; Port RE; Bengtsson T
EJNMMI Res; 2012 Jun; 2(1):35. PubMed ID: 22738240
[TBL] [Abstract][Full Text] [Related]
45. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.
Dunnwald LK; Doot RK; Specht JM; Gralow JR; Ellis GK; Livingston RB; Linden HM; Gadi VK; Kurland BF; Schubert EK; Muzi M; Mankoff DA
Clin Cancer Res; 2011 Apr; 17(8):2400-9. PubMed ID: 21364034
[TBL] [Abstract][Full Text] [Related]
46. Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis.
Cheebsumon P; Velasquez LM; Hoekstra CJ; Hayes W; Kloet RW; Hoetjes NJ; Smit EF; Hoekstra OS; Lammertsma AA; Boellaard R
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):832-42. PubMed ID: 21210109
[TBL] [Abstract][Full Text] [Related]
47. Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib.
Kasper B; Dimitrakopoulou-Strauss A; Strauss LG; Hohenberger P
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1876-82. PubMed ID: 20559633
[TBL] [Abstract][Full Text] [Related]
48. PET imaging in pediatric neuroradiology: current and future applications.
Kim S; Salamon N; Jackson HA; Blüml S; Panigrahy A
Pediatr Radiol; 2010 Jan; 40(1):82-96. PubMed ID: 19937235
[TBL] [Abstract][Full Text] [Related]
49. The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.
Kasper B; Schmitt T; Wuchter P; Dimitrakopoulou-Strauss A; Ho AD; Egerer G
Mar Drugs; 2009 Jul; 7(3):331-40. PubMed ID: 19841717
[TBL] [Abstract][Full Text] [Related]
50. F-18 FDG PET-positive fibrous dysplasia in a patient with intestinal non-Hodgkin's lymphoma.
Kim M; Kim HS; Kim JH; Jang JH; Chung KJ; Shin MK; Hwang HS; Kim BC; Jung SY
Cancer Res Treat; 2009 Sep; 41(3):171-4. PubMed ID: 19809567
[TBL] [Abstract][Full Text] [Related]
51. Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor of patient outcome.
Eary JF; O'Sullivan F; O'Sullivan J; Conrad EU
J Nucl Med; 2008 Dec; 49(12):1973-9. PubMed ID: 18997052
[TBL] [Abstract][Full Text] [Related]
52. Functional imaging techniques for evaluation of sarcomas.
Hicks RJ
Cancer Imaging; 2005 Jun; 5(1):58-65. PubMed ID: 16154821
[TBL] [Abstract][Full Text] [Related]
53. Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer.
Visvikis D; Francis D; Mulligan R; Costa DC; Croasdale I; Luthra SK; Taylor I; Ell PJ
Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):169-78. PubMed ID: 15129698
[TBL] [Abstract][Full Text] [Related]
54. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.
Rajendran JG; Wilson DC; Conrad EU; Peterson LM; Bruckner JD; Rasey JS; Chin LK; Hofstrand PD; Grierson JR; Eary JF; Krohn KA
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):695-704. PubMed ID: 12632200
[TBL] [Abstract][Full Text] [Related]
55. FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma.
Vernon CB; Eary JF; Rubin BP; Conrad EU; Schuetze S
Skeletal Radiol; 2003 Mar; 32(3):139-42. PubMed ID: 12605277
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
[TBL] [Abstract][Full Text] [Related]
57. Tumor metabolic rates in sarcoma using FDG PET.
Eary JF; Mankoff DA
J Nucl Med; 1998 Feb; 39(2):250-4. PubMed ID: 9476930
[TBL] [Abstract][Full Text] [Related]
58. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
Doot RK; Dunnwald LK; Schubert EK; Muzi M; Peterson LM; Kinahan PE; Kurland BF; Mankoff DA
J Nucl Med; 2007 Jun; 48(6):920-5. PubMed ID: 17504870
[TBL] [Abstract][Full Text] [Related]
59. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma.
Eary JF; Conrad EU; Bruckner JD; Folpe A; Hunt KJ; Mankoff DA; Howlett AT
Clin Cancer Res; 1998 May; 4(5):1215-20. PubMed ID: 9607579
[TBL] [Abstract][Full Text] [Related]
60. Carbon-11-thymidine and FDG to measure therapy response.
Shields AF; Mankoff DA; Link JM; Graham MM; Eary JF; Kozawa SM; Zheng M; Lewellen B; Lewellen TK; Grierson JR; Krohn KA
J Nucl Med; 1998 Oct; 39(10):1757-62. PubMed ID: 9776283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
